Eli Lilly (LLY) shares are in the spotlight on Monday after the pharmaceutical behemoth announced a $2.88 billion acquisition of Merida Biosciences. The all-cash acquisition of the biotechnology company marks LLY’s latest move to expand its drug pipeline.
Note that Eli Lilly stock has been a blockbuster investment in recent months, currently up roughly 35% versus its year-to-date low in late April.